EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
[HTML][HTML] Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases
X Yu, Y Fan - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
[HTML][HTML] Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010 …
Simple Summary Radiotherapy, in the form of either whole-brain radiotherapy (WBRT) or
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
stereotactic radiosurgery (SRS), continues as the standard of care for patients of non-small …
Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases
X Yu, J Sheng, G Pan, Y Fan - International Journal of Cancer, 2021 - Wiley Online Library
Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
H Bai, B Han - OncoTargets and therapy, 2017 - Taylor & Francis
Brain metastases are usual in non-small-cell lung cancer (NSCLC) with poor prognosis and
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
few available therapeutic options. This retrospective study aims to evaluate the efficacy of …
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
[HTML][HTML] A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain …
L Cai, J Zhu, X Zhang, S Lin, X Su, P Lin, K Chen… - Journal of neuro …, 2014 - Springer
We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery …
kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery …
[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present …
C Proto, M Imbimbo, R Gallucci, A Brissa… - … lung cancer research, 2016 - ncbi.nlm.nih.gov
Lung cancer is one of the major causes of cancer related mortality worldwide. Brain
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in …
[HTML][HTML] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
K Dong, W Liang, S Zhao, M Guo, Q He… - Translational Lung …, 2019 - ncbi.nlm.nih.gov
Background It has been confirmed that epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
inhibitors (EGFR-TKIs) presented better efficacy than brain radiotherapy (brain RT) in the …
[HTML][HTML] The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
TH Chiu, PH Tung, CH Huang, JS Ju, ACC Huang… - Scientific Reports, 2022 - nature.com
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …